MEI Pharma Q3 2024 Adj EPS $(1.37) Beats $(1.52) Estimate, Sales $5.890M Beat $37.500K Estimate

5/9/24 4:54:43 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MEIP alert in real time by email

MEI Pharma (NASDAQ:MEIP) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.52) by 9.87 percent. The company reported quarterly sales of $5.890 million which beat the analyst consensus estimate of $37.500 thousand by 15.61K percent. This is a 0.07 percent decrease over sales of $5.894 million the same period last year.

Get the next $MEIP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MEIP

Date	Price Target	Rating	Analyst
7/23/2024		Buy → Hold	Laidlaw
3/25/2022	$4.00 → $1.00	Buy → Hold	Jefferies
3/25/2022	$13.00 → $2.00	Overweight → Equal Weight	Wells Fargo
3/25/2022	$6.00 → $2.00	Buy → Hold	Stifel
2/3/2022	$4.00	Buy	Jefferies

More analyst ratings

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme
11/12/24 4:05:00 PM ET
$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care
MEI Pharma Reports Fiscal Year End 2024 Cash Position
Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs
9/19/24 4:01:00 PM ET
$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company's exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders. There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been c
8/12/24 8:30:00 AM ET
$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care

$MEIP
Financials

Live finance-specific insights

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme
11/12/24 4:05:00 PM ET
$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care
MEI Pharma Reports Fiscal Year End 2024 Cash Position
Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs
9/19/24 4:01:00 PM ET
$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritization of Voruciclib Program Development-- -- MEI Begins Fourth Fiscal Quarter with $56.6 Million in Cash -- MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.
5/9/24 4:02:00 PM ET
$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care

MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company's succession planning, Brian Drazba's tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin (Jay) File as his successor. Mr. File joined the Company on June 12, 2023 as Executive Vice President, Finance and will be appointed Chief Financial Officer upon Mr. Drazba's departure. "Brian has been a true asset to MEI providing invaluable fiscal and business leadership as we advanced our clinical programs and executed various transactions, incl
6/13/23 8:00:00 AM ET
$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care
MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company's previously announced succession plan, Daniel P. Gold, Ph.D's tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company's board of directors has appointed David M. Urso as his successor. Mr. Urso, who joined the Company in 2014 and has been serving as the company's chief operating officer since 2018, will also join the board of directors. Dr. Gold will remain on MEI's board, where he will continue to share his extensive knowledge and experience with the company.
6/2/23 8:00:00 AM ET
$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care
MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer
MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese's appointment is effective immediately. Ms. Frese joins MEI with over 30 years of human resource experience across a variety of industries, including biotech, consulting, hospitality, and engineering. Most recently, she served as chief human resources officer at Vyripharm En
6/22/22 8:00:00 AM ET
$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care

MEI Pharma Q3 2024 Adj EPS $(1.37) Beats $(1.52) Estimate, Sales $5.890M Beat $37.500K Estimate

Chat with this insight

Recent Analyst Ratings for $MEIP

$MEIP SEC Filings

MEI Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by MEI Pharma Inc.

MEI Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

$MEIP Press Releases

Fastest customizable press release news feed in the world

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

MEI Pharma Reports Fiscal Year End 2024 Cash Position

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

$MEIP Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Wood Steven D was granted 3,100 shares, increasing direct ownership by 246% to 4,359 units (SEC Form 4)

Flynn James P was granted 7,900 shares (SEC Form 4)

SEC Form 4 filed by Flynn James P (Amendment)

$MEIP Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Anson Funds Management Lp bought $329,331 worth of shares (48,060 units at $6.85) (SEC Form 4)

Funicular Funds, Lp bought $219,554 worth of shares (32,040 units at $6.85) (SEC Form 4)

SEC Form 4: Anson Funds Management Lp bought $938,226 worth of shares (153,600 units at $6.11)

$MEIP Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

MEI Pharma downgraded by Laidlaw

MEI Pharma downgraded by Jefferies with a new price target

MEI Pharma downgraded by Wells Fargo with a new price target

$MEIP Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

SEC Form SC 13D/A filed by MEI Pharma Inc. (Amendment)

$MEIP Financials

Live finance-specific insights

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

MEI Pharma Reports Fiscal Year End 2024 Cash Position

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

$MEIP Market Insights

Live Market Insights

$MEIP Leadership Updates

Live Leadership Updates

Laidlaw & Co. Downgrades MEI Pharma to Hold

Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

MEI Pharma shares are trading higher after the company announced it is considering strategic alternatives.

MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

Recent Analyst Ratings for
$MEIP

$MEIP
SEC Filings

$MEIP
Press Releases

$MEIP
Insider Trading

$MEIP
Insider Purchases

$MEIP
Analyst Ratings

$MEIP
Large Ownership Changes

$MEIP
Financials

$MEIP
Market Insights

$MEIP
Leadership Updates